Physician
Beityakov, Mordechai
Beityakov, Mordechai was paid $7.68M by Medicaid between Jan 2018 and Dec 2024, across 51 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 66% of everything it billed.
33Billing provider infoBEITYAKOV, MORDECHAI
BROOKLYN, NY 11210
BROOKLYN, NY 11210
33aNPI1780679530assigned 09/19/2005
33bProvider typePediatrics Physician
28Total paid$7.68M
24GClaims180,174
24DCodes billed51
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in New York
Rank by total paid#35 of 1,983
Median peer was paid$17K
This provider vs. median453×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,556 | $782K | |
| 2019 | 24,973 | $918K | |
| 2020 | 28,419 | $1.12M | |
| 2021 | 34,587 | $1.39M | |
| 2022 | 27,423 | $1.12M | |
| 2023 | 22,707 | $1.16M | |
| 2024incomplete | 20,509 | $1.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 66% | 87,289 | 59,124 | $5.05M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 4.2% | 7,774 | 7,615 | $326K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.1% | 4,022 | 3,956 | $314K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.0% | 3,933 | 3,922 | $306K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.4% | 28,928 | 24,928 | $258K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.8% | 2,593 | 2,584 | $218K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.8% | 3,032 | 2,613 | $217K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.1% | 4,858 | 4,257 | $164K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 4,265 | 3,728 | $142K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.8% | 10,846 | 5,048 | $139K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.4% | 1,276 | 1,272 | $108K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.3% | 1,190 | 1,188 | $101K |
39 more codes
| 99214 | Doctor's office visit, returning patient (more involved) | 1.2% | 1,136 | $95K |
| 69210 | <1% | 1,340 | $42K | |
| 90677 | <1% | 164 | $38K | |
| 99050 | <1% | 2,573 | $31K | |
| 99188 | <1% | 2,958 | $30K | |
| 12001 | <1% | 279 | $19K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 429 | $17K |
| 99381 | <1% | 182 | $14K | |
| 90461 | <1% | 435 | $13K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,925 | $8K |
| 83655 | <1% | 739 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 199 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 234 | $3K |
| D1206 | Topical application of fluoride varnish | <1% | 95 | $3K |
| 88738 | <1% | 693 | $3K | |
| 81002 | <1% | 1,152 | $3K | |
| 90656 | <1% | 155 | $2K | |
| 87634 | <1% | 65 | $2K | |
| 90660 | <1% | 94 | $1K | |
| 36410 | <1% | 97 | $1K | |
| 0001A | <1% | 29 | $1K | |
| 81000 | <1% | 349 | $1K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 16 | $1K |
| 0002A | <1% | 26 | $1K | |
| 99441 | <1% | 37 | $462.89 | |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 123 | $367.18 |
| 81003 | <1% | 115 | $231.79 | |
| 86580 | <1% | 12 | $82.46 | |
| 90715 | <1% | 12 | $78.14 | |
| 90698 | <1% | 90 | $17.85 | |
| 90670 | <1% | 16 | $17.85 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 86 | $10.94 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 27 | $10.05 |
| 90619 | 0% | 59 | $0.00 | |
| 90744 | 0% | 110 | $0.00 | |
| 90696 | 0% | 25 | $0.00 | |
| 90633 | 0% | 51 | $0.00 | |
| 90700 | 0% | 15 | $0.00 | |
| 90710 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.